Apelin-13 protects against myocardial infarction-induced myocardial fibrosis

Zhang,Xuemin; Hu,Wenyu; Feng,Feng; Xu,Jian; Wu,Fang

doi:10.3892/mmr.2016.5163

Apelin-13 protects against myocardial infarction-induced myocardial fibrosis

Authors:
- Xuemin Zhang
- Wenyu Hu
- Feng Feng
- Jian Xu
- Fang Wu
View Affiliations

Affiliations: Department of Cardiology, Shenyang First People's Hospital, Shenyang, Liaoning 110041, P.R. China, Department of Cardiology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Cardiology, The Second Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110034, P.R. China
Published online on: April 22, 2016 https://doi.org/10.3892/mmr.2016.5163
Pages: 5262-5268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myocardial infarction is a serious health threat. Apelin is an endogenous ligand of angiotensin II receptor-like 1 (APJ) and the apelin/APJ system is associated with various types of heart disease. However, whether apelin protects against myocardial infarction‑induced myocardial fibrosis remains unclear. The present study aimed to investigate the function of apelin‑13 during myocardial infarction‑induced myocardial fibrosis, and to determine the mechanism underlying the effects of apelin‑13. Apelin‑13 was demonstrated to improve left ventricular function and results of hematoxylin and eosin staining, Masson's trichrome staining and western blotting showed that apelin‑13 attenuated myocardial fibrosis. Further mechanistic investigation was performed by enzyme‑linked immunosorbent assay, western blotting and electrophoretic mobility shift assay. The results demonstrated that apelin‑13 inhibited the activation of nuclear factor (NF)‑κB signaling in vitro and in vivo. To the best of our knowledge, the present study was the first to demonstrate that apelin‑13 may attenuate myocardial infarction‑induced myocardial fibrosis, and that this protective function may be mediated by inhibition of NF‑κB signaling. The present study suggests a theoretical basis for the effects of apelin‑13 and provides insight into the potential clinical application of apelin-13.

View Figures

View References

1	Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart- disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 115:e69–e171. 2007. View Article : Google Scholar
2	Quazi R, Palaniswamy C and Frishman WH: The emerging role of apelin in cardiovascular disease and health. Cardiol Rev. 17:283–286. 2009. View Article : Google Scholar : PubMed/NCBI
3	Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, Yu F, Duan XH, Tang CS and Qi YF: Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 28:2023–2029. 2007. View Article : Google Scholar : PubMed/NCBI
4	Japp AG and Newby DE: The apelin-APJ system in heart failure: Pathophysiologic relevance and therapeutic potential. Biochem Pharmacol. 75:1882–1892. 2008. View Article : Google Scholar : PubMed/NCBI
5	Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K and Fujimiya M: The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 99:87–92. 2001. View Article : Google Scholar : PubMed/NCBI
6	Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, et al: The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 65:73–82. 2005. View Article : Google Scholar
7	Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ and Woo YJ: Apelin has in vivo inotropic effects on normal and failing hearts. Circulation. 110(11 Suppl 1): II187–II193. 2004. View Article : Google Scholar : PubMed/NCBI
8	Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M and Ruskoaho H: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 91:434–440. 2002. View Article : Google Scholar : PubMed/NCBI
9	Chandrasekaran B, Dar O and McDonagh T: The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail. 10:725–732. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ and Tang CS: Apelin protects heart against ischemia/reperfusion injury in rat. Peptides. 30:1144–1152. 2009. View Article : Google Scholar : PubMed/NCBI
11	Tao J, Zhu W, Li Y, Xin P, Li J, Liu M, Li J, Redington AN and Wei M: Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol. 301:H1471–H1486. 2011. View Article : Google Scholar : PubMed/NCBI
12	Barnes G, Japp AG and Newby DE: Translational promise of the apelin - APJ system. Heart. 96:1011–1016. 2010. View Article : Google Scholar : PubMed/NCBI
13	Patten RD, Aronovitz MJ, Deras-Mejia L, Pandian NG, Hanak GG, Smith JJ, Mendelsohn ME and Konstam MA: Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol. 274:H1812–H1820. 1998.PubMed/NCBI
14	Ahn D, Cheng L, Moon C, Spurgeon H, Lakatta EG and Talan MI: Induction of myocardial infarcts of a predictable size and location by branch pattern probability-assisted coronary ligation in C57BL/6 mice. Am J Physiol Heart Circ Physiol. 286:H1201–H1207. 2004. View Article : Google Scholar : PubMed/NCBI
15	Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, Yang J, Chang JK, Tang CS and Qi YF: Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept. 133:147–154. 2006. View Article : Google Scholar
16	Rastaldo R, Cappello S, Folino A, Berta GN, Sprio AE, Losano G, Samaja M and Pagliaro P: Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol. 300:H2308–H2315. 2011. View Article : Google Scholar : PubMed/NCBI
17	Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, et al: Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: Therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc. 2:e0002492013. View Article : Google Scholar : PubMed/NCBI
18	Azizi Y, Faghihi M, Imani A, Roghani M and Nazari A: Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides. 46:76–82. 2013. View Article : Google Scholar : PubMed/NCBI
19	Cui RR, Mao DA, Yi L, Wang C, Zhang XX, Xie H, Wu XP, Liao XB, Zhou H, Meng JC, et al: Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino Acids. 39:1193–1200. 2010. View Article : Google Scholar : PubMed/NCBI
20	Eskew RT Jr, Stromeyer CF III, Picotte CJ and Kronauer RE: Detection uncertainty and the facilitation of chromatic detection by luminance contours. J Opt Soc Am A. 8:394–403. 1991. View Article : Google Scholar : PubMed/NCBI
21	Porter KE and Turner NA: Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther. 123:255–278. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH, Wanecq E, Valet P, et al: Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 33:2360–2369. 2012. View Article : Google Scholar
23	Griendling KK, Tsuda T, Berk BC and Alexander RW: Angiotensin II stimulation of vascular smooth muscle cells. Secondary signalling mechanisms. Am J Hypertens. 2:659–665. 1989. View Article : Google Scholar : PubMed/NCBI
24	Kagami S, Border WA, Miller DE and Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 93:2431–2437. 1994. View Article : Google Scholar : PubMed/NCBI
25	Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE and Smith LH: Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens. 29:724–731. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kleinz MJ and Baxter GF: Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept. 146:271–277. 2008. View Article : Google Scholar
27	Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM and Smith CC: Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol. 102:518–528. 2007. View Article : Google Scholar : PubMed/NCBI
28	Yang Y, Zhang X, Cui H, Zhang C, Zhu C and Li L: Apelin-13 protects the brain against ischemia/reperfusion injury through activating PI3K/Akt and ERK1/2 signaling pathways. Neurosci Lett. 568:44–49. 2014. View Article : Google Scholar : PubMed/NCBI
29	Atluri P, Morine KJ, Liao GP, Panlilio CM, Berry MF, Hsu VM, Hiesinger W, Cohen JE and Joseph Woo Y: Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett. 12:127–138. 2007. View Article : Google Scholar